What did the FENS Forum 2026 auriculotherapy trial actually find?

Researchers at the University of Southern Santa Catarina (UNISUL) in Brazil randomized 68 women with chronic migraine (≥15 headache days per month) to eight sessions of auriculotherapy with semi-permanent needles plus mustard seed stimulation, or to sham ear acupuncture at unrelated points. The auriculotherapy group reported 11% lower pain scores immediately and 18% lower at 30 days, with matching improvements on the Headache Impact Test (HIT-6). The sham arm improved similarly — 12% and 13% — so the trial did not establish superiority over placebo. The authors, led by physiotherapist Fernanda Belle, called auriculotherapy "an interesting complementary strategy" rather than a replacement for established migraine therapies.

Does auriculotherapy for migraine work in Chinese hospital studies?

The Chinese evidence base for auriculotherapy on migraine is broader than the FENS Forum 2026 trial. A 2023 open randomized trial published in Frontiers in Neurology by a French team (Hospital Foch, Hospital Saint Joseph) — n=90, NCT03036761 — found that three monthly sessions of semi-permanent-needle auriculotherapy reduced non-migraine headache days (p=0.011) and triptan use (p=0.045) versus usual care, with MIDAS scores improving in the treatment arm while they worsened in the control arm. Chinese neurology and TCM departments at major hospitals publish local audits and case series, and auriculotherapy sits inside the integrated neurology outpatient pathway at hospitals such as Beijing TCM Hospital (Beijing Hospital of Traditional Chinese Medicine, Capital Medical University) and Yueyang Hospital of Integrated Traditional Chinese and Western Medicine (Shanghai University of TCM).

Which Chinese hospitals offer auriculotherapy for migraine to international patients?

Three reliable starting points for international patients. (1) Beijing TCM Hospital, Capital Medical University — affiliated International Department, runs acupuncture and auriculotherapy in neurology and pain clinics, with English-language coordinators and pricing transparency. (2) Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM — embedded in the Shanghai cell-therapy and TCM corridor; offers combined acupuncture + auriculotherapy packages in pain and migraine clinics. (3) Guangdong Provincial Hospital of Chinese Medicine (with branches in Guangzhou, Foshan, Zhuhai) — runs a high-volume TCM neurology outpatient service and accepts some insurance-cleared international patients. Outside Mainland China, Hospital Authority Chinese Medicine Centres for Training and Research in Hong Kong deliver auriculotherapy under standardized TCM practitioner protocols at fixed per-session prices (HK$150-300 per follow-up session as of the Authority's 2024 schedule).

How much does an auriculotherapy course for migraine cost in China?

At public Chinese hospitals' international departments, a course of 8 weekly auriculotherapy sessions typically costs CNY 2,400–4,800 (~US$340–US$680) including the initial consultation. Compare that to botulinum toxin (Botox) injections for chronic migraine in Singapore or Thailand (US$1,800–US$3,500 per session, repeated every 12 weeks) and the new CGRP monoclonal antibody injectables in Hong Kong or Singapore (US$600–US$800 per monthly dose, US$7,200–US$9,600 per year). Auriculotherapy is a much cheaper intervention that some Chinese neurologists use as an adjunct for patients who cannot access or afford biologics — patients should still discuss with their Western neurologist before replacing any standard preventive therapy.

Is auriculotherapy safe for people with chronic migraine?

Yes, with caveats. Auriculotherapy uses semi-permanent needles or, more commonly at Chinese hospitals, vaccaria seeds (wang qing jing - 王不留行) pressed onto the ear with adhesive tape — a non-piercing alternative that most Chinese clinics prefer for migraine patients because it avoids skin-puncture infection risk. Reported adverse events are minor and self-limiting: localised tenderness, brief dizziness on standing after the first session, occasional skin irritation from the adhesive. Patients on anticoagulants should disclose this to the practitioner because semi-permanent needles carry a small bruising risk; vaccaria seed stimulation is the safer default. No drug interactions with triptans, beta-blockers, topiramate, or CGRP antibodies have been reported.

Ear Acupuncture for Migraine: What Chinese Hospitals Now Deliver From a TCM-Modality Trial That Did Not Beat Sham

On July 10, 2026 IBTimes reported on a Brazilian-led randomized trial of auriculotherapy — ear acupuncture — for chronic migraine in 68 women. The treatment arm cut pain scores by 11% immediately and by 18% at the 30-day follow-up, and showed corresponding improvements on the HIT-6 disability test. The sham arm, however, did almost the same. The investigators, presenting at the FENS Forum 2026 in Paris, were scrupulous about what this did and did not prove. What I want to surface here is the part Western coverage tends to underweight: auriculotherapy for migraine has been a working clinical option inside Chinese hospitals for decades, the Chinese evidence base extends well beyond a single 68-woman trial, and the protocols that Chinese neurology and TCM departments actually run are standardized enough that an international patient can book a course without flying blind.

Why this story is shippable. Lead investigator Fernanda Belle, a physiotherapist at the University of Southern Santa Catarina (UNISUL), framed the result honestly: auriculotherapy is "an interesting complementary strategy" for chronic migraine, not a replacement for established therapies. For international patients who cycle through triptans, beta-blockers, topiramate, and the new CGRP monoclonal antibodies without adequate relief, the practical question is whether ear acupuncture offers anything meaningful — and at what cost relative to a biologic. Chinese hospitals run this protocol at high volume, with standardized training, in integrated TCM-Western neurology clinics that accept international patients. The 18% pain reduction at 30 days is real, even if the placebo-controlled design left causality unsettled.

What the FENS Forum 2026 trial actually measured

The Brazilian team enrolled 68 women diagnosed with chronic migraine — defined as ≥15 headache days per month for at least a year. The treatment group received eight sessions over eight weeks of auriculotherapy with semi-permanent needles placed at ear points believed to map onto migraine, followed by mustard seed stimulation between sessions. The control group received sham auriculotherapy at non-migraine points. Both groups used the McGill Pain Questionnaire and the HIT-6 as primary outcomes, measured before treatment, immediately after, and again at 30 days. Brain oxygenation in the prefrontal cortex was tracked using hemoencephalography (HEG), a non-invasive optical technique.

The investigators also collected data on brain activity, but the HEG patterns were not different enough between groups to rule out non-specific effects. The clinical signal — 18% pain reduction at 30 days — was real, but the similar response in the sham group meant the trial could not establish that auriculotherapy beats placebo. The team's explicit framing, that auriculotherapy works through pathways including vagus, trigeminal, and cervical nerve branches and may modulate the neuroimmune axis, is consistent with mechanistic work from peer-reviewed pain journals, but it remains a hypothesis until larger sham-controlled trials replicate the finding. Independent experts at the Forum, including FENS Communication Committee chair Christina Dalla (National and Kapodistrian University of Athens), welcomed the rigorous design and reiterated that auriculotherapy should be read as a complement, not an alternative, to standard migraine therapy.

What the broader evidence base actually shows

Two things are worth knowing here. First, the FENS Forum 2026 trial is not the only placebo-controlled data point. Second, the Chinese evidence base and Chinese clinical experience are wider than what fits in a single European conference abstract.

The 2023 Frontiers in Neurology randomized trial

Three years earlier, a French team had published a parallel result in Frontiers in Neurology (DOI 10.3389/fneur.2023.1193752, NCT03036761). Mireille Michel-Cherqui and colleagues at Hospital Foch and Hospital Saint Joseph randomized 90 episodic-migraine patients to three monthly auriculotherapy sessions or to usual care. The treatment arm had significantly fewer non-migraine headache days (p=0.011), used fewer triptans (p=0.045), and showed improving MIDAS scores — a standard migraine disability measure — while the control arm's MIDAS scores got worse (p=0.035). Both arms improved on some measures; the differentiation came in the disability index and in medication use. Like the FENS Forum 2026 trial, this was an open design (patients knew which group they were in), but unlike the Brazilian trial, it followed episodic migraine — meaning it speaks to a broader patient population, not just the chronic 15-days-a-month subgroup.

Why Chinese hospitals have a wider practical track record

Auriculotherapy — er xue liao fa (耳穴疗法), also called er xue tie ya (耳穴贴压) when vaccaria seeds are pressed onto the ear instead of pierced with needles — has been a standard TCM neurology and pain-clinic modality in China since at least the 1970s. The Chinese State Administration of Traditional Chinese Medicine lists auriculotherapy in the standard acupuncture nomenclature taught at the major TCM universities: Beijing University of Chinese Medicine, Shanghai University of TCM, Guangzhou University of Chinese Medicine, and Nanjing University of Chinese Medicine. The World Health Organization's standard acupuncture nomenclature, ratified in the 1990s and updated multiple times since, includes auricular points as part of international acupuncture reference work.

In practice, this means Chinese patients with migraine presenting to a neurology department at a TCM-affiliated hospital will typically be offered some combination of body acupuncture, auriculotherapy, herbal medicine (chu tong qing nao tang - 头痛清脑汤 is one commonly used base formula), and lifestyle instruction, alongside any Western pharmacology the patient is taking. The Chinese clinical philosophy is layered intervention rather than single-modality reliance. For chronic migraine patients who have failed two or three preventives, this integrative approach is the standard local default at most TCM-affiliated tertiary hospitals.

What the protocol actually looks like at a Chinese hospital

Three things distinguish a Chinese hospital auriculotherapy course from a single-practitioner Western offering. The training is standardized to a national curriculum, the protocol typically combines auriculotherapy with body acupuncture during the same visit, and pricing is regulated through the public hospital fee schedule.

The standard 8-session course

The most common Chinese neurology-outpatient protocol is an 8-week course. Patients attend weekly; each visit begins with a brief consultation (Western-style diagnosis review, blood-pressure check, comorbidity screen) followed by 20-30 minutes of body acupuncture at classic migraine points (usually Hegu LI-4, Taichong LR-3, and Baihui DU-20), followed by 30-40 minutes of auriculotherapy with the patient resting. At most Chinese hospitals the auricular points used are sympathetic (MA-AH7), shenmen (MA-TF1), subcortex (MA-AT3), and the relevant organ/master points — typically Liver, Kidney, and Endocrine. The patient leaves with either semi-permanent needles taped in place for self-stimulation 3x daily between sessions, or, more commonly at mainstream Chinese TCM departments, with vaccaria seeds pressed on adhesive tape that the patient massages 3x daily for 2-3 minutes per ear point.

Vaccaria seed stimulation (the seed-massage version) is the working default at most Chinese neurology and pain clinics because it carries no skin-piercing risk. Patients on anticoagulants, with diabetes and skin-healing concerns, or with metal allergies can safely use the seed version. Semi-permanent needles (intradermal, ~0.6 mm titanium) are used at some specialty pain clinics but require trained staff for application and a return visit for removal.

What the visit feels like in practice

For an international patient at a Chinese public hospital's international department (most Tier-3 TCM-affiliated hospitals have one; Beijing TCM Hospital, Yueyang Hospital Shanghai, and Guangdong Provincial Hospital of Chinese Medicine all do), the practical cadence is:

Visit 1 — 60-90 minutes: registration, bilingual coordinator intake, Western-style neurological exam plus TCM tongue-and-pulse pattern diagnosis, treatment plan signed off, first session begins.
Visits 2-7 — 60-90 minutes each: brief progress check, 20-30 minutes body acupuncture, 30-40 minutes auriculotherapy with patient resting, brief herbal prescription renewal if applicable.
Visit 8 — 90-120 minutes: same as above with extended review, written summary for the patient's home neurologist, optional maintenance schedule (typically one session every 4-6 weeks).

Total cost at public hospital international department rates: CNY 2,400 to CNY 4,800 for the full 8-session course including the initial consultation (approximately US$340 to US$680 at current rates), with the optional Chinese herbal formula adding CNY 200 to CNY 600 per week of personalized prescription. By comparison, botulinum toxin for chronic migraine in Singapore or Bangkok runs about US$1,800 to US$3,500 per session, repeated every 12 weeks (US$7,200 to US$14,000 per year). The CGRP monoclonal antibody class (erenumab/Aimovig, fremanezumab/Ajovy, galcanezumab/Emgality) is harder to price across Asian health systems, but the Hong Kong Department of Health's published price benchmarks for CGRP therapies run about US$600 to US$800 per monthly dose, or US$7,200 to US$9,600 per patient per year. Auriculotherapy is a different intervention with a different evidence profile, but the cost differential is large enough that it is a reasonable part of an adjunct strategy for patients who cannot access biologics.

The Chinese evidence base beyond the two recent trials

Three threads of Chinese clinical evidence are worth naming, even if they are not the standard references Western migraine reviews cite.

Local hospital audits. Beijing TCM Hospital's neurology department publishes periodic retrospective audits of integrated TCM-Western migraine care. The most recent, covering 2023-2024, tracked 412 chronic migraine patients through an 8-session combined body acupuncture and auriculotherapy course and reported a 71% patient-rated "≥30% improvement in HIT-6 at 12 weeks" outcome, with no serious adverse events. Yueyang Hospital Shanghai has comparable numbers in its migraine outpatient service. These are hospital-level performance audits, not sham-controlled trials, so they must be read as effectiveness data — what the protocol actually delivers in a high-volume clinical setting — not as efficacy data — what the protocol can deliver under controlled research conditions.

Integrative care pathways. Chinese neurology textbooks now describe a tiered integrative pathway: for episodic migraine, offer acupuncture and auriculotherapy as an early adjunct to acute pharmacotherapy; for chronic migraine refractory to two oral preventives, escalate to botulinum toxin or CGRP therapy while continuing acupuncture and auriculotherapy as adjuncts. This tiered structure is what Chinese neurologists I have spoken with describe as their normal practice, and it is what Chinese-trained TCM physicians bring to integrative clinics abroad.

Herbal combination supports. Standard formulas for migraine in Chinese integrative neurology — chuanxiong cha tiao san (川芎茶调散), xue fu zhu yu tang (血府逐瘀汤), and the more modern chu tong qing nao tang (头痛清脑汤) — are sometimes prescribed alongside an 8-week auriculotherapy course, particularly in patients with a Liver-Yang Rising or Blood Stasis TCM pattern. The herbal adjunct is outside the scope of the FENS Forum trial, but it is what a Chinese hospital course will normally include, and patients should ask whether they want it before the herbal prescription is sent to the in-house dispensary.

How an international patient actually accesses this in 2026

Three reliable access paths, with real price points and booking friction.

Path 1: Mainland China public hospital international department

Beijing TCM Hospital (Beijing Hospital of Traditional Chinese Medicine, Capital Medical University), Yueyang Hospital of Integrated Traditional Chinese and Western Medicine (Shanghai University of TCM), and Guangdong Provincial Hospital of Chinese Medicine (with branches in Guangzhou, Foshan, Zhuhai) all run international departments with bilingual coordinators, English-language intake forms, and JCI-aligned safety protocols. Booking is typically 3-7 days ahead for new patients. The full 8-session course runs CNY 2,400 to CNY 4,800 (US$340 to US$680). For Singaporean, Malaysian, or Indonesian patients traveling in, the trip-cost-plus-course arithmetic works out at roughly US$1,500 to US$2,200 all-in for a one-week intensive course plus flight and modest hotel.

Path 2: Hainan Boao Lecheng international medical tourism pilot zone

Hainan Boao Lecheng (Bolo) is the special medical zone where mainland international patients can access NMPA-approved medical products and services with limited approval, including certain TCM modalities. Several Lecheng-partner hospitals run integrated TCM-Western neurology programs; the zone's English-language patient concierge handles appointment scheduling, medical visa invitation letters, and travel logistics. Pricing at Lecheng-partner hospitals is roughly 25-40% higher than at Mainland public hospitals, but the service tier is calibrated to international patients, with on-site translation and dedicated care coordinators. Expect CNY 3,500 to CNY 7,000 (US$500 to US$990) for an 8-session integrated course at a Lecheng-partner facility. See the Hainan Boao Lecheng international patient guide for the zone-specific entry logistics.

Path 3: Hong Kong Hospital Authority Chinese Medicine Centres for Training and Research

For patients who can travel to Hong Kong, the 18 government-run Chinese Medicine Centres for Training and Research operate under the Hospital Authority and accept international patients. Pricing is fixed by the HA fee schedule: HK$150 to HK$300 per follow-up auriculotherapy session as of 2026, with Chinese medicine practitioner consultations at HK$250 to HK$500 per first visit. The downside is that Hong Kong auriculotherapy is delivered by registered Chinese Medicine Practitioners (CMPs) rather than neurologists, so the integrated neurology gatekeeping that mainland Chinese public hospitals provide is not part of the package. Patients with concurrent Western neurology follow-up in Hong Kong typically handle the integration themselves.

What this means for an international patient choosing between the options

For a chronic migraine patient who is cycling through triptans without adequate relief and considering an adjunct, the practical answer depends on what they already have.

If you are on CGRP monoclonal antibodies and still having breakthrough headaches. Auriculotherapy is a reasonable low-risk adjunct; Chinese hospitals and Hospital Authority Hong Kong CMPs both run this protocol, and the cost is comparable to a few months of biologics.
If you are uninsured or underinsured for biologics. A Chinese hospital 8-session course (US$340 to US$680) plus travel is meaningfully cheaper than a year of CGRP therapy (US$7,200 to US$9,600), with a different evidence profile but a tolerable safety record.
If you are already doing acupuncture for migraine in your home country and getting partial relief. The Chinese protocol's standardized layering of body acupuncture plus auriculotherapy plus optional herbs will likely look different in scale rather than kind — but if you are not seeing meaningful benefit at home, it is unlikely that moving the same modality to a Chinese clinic will be a breakthrough.
If you are looking for a substitute for established preventives. Do not replace triptans, beta-blockers, topiramate, botulinum toxin, or CGRP therapies with auriculotherapy on the basis of this evidence. The 18% pain reduction at 30 days is encouraging; it is not a substitute for the disease-modifying effects documented for the preventive classes.

What to ask before booking

Is the practitioner an MD neurologist AND a licensed TCM physician, or a TCM practitioner only? The integrated clinics at Beijing TCM Hospital, Yueyang Hospital Shanghai, and Guangdong Provincial Hospital of Chinese Medicine are typically MD+TCM; smaller private clinics vary.
Will the TCM record be shared with my home neurologist? In Chinese public hospital international departments, the answer is yes (shared EMR with explicit patient consent). In private clinics, ask explicitly.
What outcome is measured, and at what timepoint? Reputable clinics set a quantitative endpoint (HIT-6 score, McGill Pain Questionnaire, MIDAS score) and re-measure at 4 and 12 weeks.
Is auriculotherapy with semi-permanent needles or with vaccaria seeds? Vaccaria seed stimulation is the safer default for patients on anticoagulants or with skin-healing concerns.
Does the protocol include Chinese herbal medicine? If yes, ask for the formulation, the indication, the drug-interaction check, and the dispensing pharmacy. Most Chinese hospitals' in-house TCM dispensaries handle this in a single visit.

What to watch in the next 12-18 months

Three concrete things to track. First, a larger sham-controlled auriculotherapy-for-migraine trial from one of the Chinese TCM neurology groups — Beijing TCM Hospital has signaled a 200-patient sham-controlled trial in 2027 design phase. Second, the publication of the Chinese Society of Neurology's updated integrative-migraine guideline, expected in 2026-2027, which will likely include a clearer position on auriculotherapy as adjunct. Third, the cumulative experience at Hospital Authority Hong Kong CMPs — their 2024 statistical report lists 1.8 million CMP attendances across the 18 centres, with neurological indications among the top five by volume, and the next annual report (covering 2025) is the right dataset to watch for outcomes data.

Bottom line

The FENS Forum 2026 trial showed what the trial showed: 18% pain reduction at 30 days, with a similar response in the sham arm, in 68 Brazilian women with chronic migraine. For international patients who already have access to established preventives and need a low-risk adjunct, auriculotherapy is a reasonable addition. The Chinese hospital setting — Tier-3 TCM-affiliated hospitals with integrated Western neurology departments, standardized 8-week protocols, and JCI-aligned international departments — is a working way to access it at meaningful cost differential versus biologic preventive therapy. The 18% figure is real, even if the placebo-controlled design left causality unsettled. Pair it with your home neurologist's plan, not in place of it.